Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal glucagon for MASLD associated with bioinactive glucagon
jRCTs041260122Recruiting
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of glucagon in metabolic dysfunction-associated steatotic liver disease (MASLD) and glucagon abnormality. Primary endpoint: Change in liver fibrosis by MR elastography. Started Sep 2026; status: recruiting.
02
Drugs
glucagon
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)glucagon abnormality
Beyond the preview
Go deeper on jRCTs041260122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260122.